Prescription Portability
Whether you can take your prescription elsewhere.
Whether you can take your prescription elsewhere.
Across the 20 programmes we price, all-in cost runs from $145 a month at the starter dose, with the cheapest first year at about $1,740 (NexLife, $145 a month at a 2.4 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
First-year all-in cost
What you are actually buying
A telehealth subscription bundles four things that are frequently priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.
The question that separates care from a vending machine
Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn someone away.
What the care model changes about your bill
Video visits, included laboratory work and real clinician access cost money to provide, and programmes that provide them are rarely the cheapest. That is not a scandal — it is what you are paying for. The failure is paying a premium for an asynchronous questionnaire that a cheaper programme provides identically.
What we could not verify
Response times, whether the same clinician sees you twice, and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent from every table rather than estimated.
What a subscription actually buys
Four things, usually priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to somebody who will answer a question. Programmes differ enormously in how much of each they provide, and the difference is invisible in a monthly price.
The most expensive programmes are not reliably the ones providing the most. Some are simply carrying more marketing cost, and a cheaper programme that names its pharmacy and answers messages within a day is providing more of what matters.
The test that separates care from a vending machine
Can this programme decline to prescribe? A service that guarantees approval before a clinician has seen your history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn somebody away.
Ask what histories would stop a prescription being written. A programme that can answer has clinical governance; one that treats the question as an obstacle does not.
Where asynchronous care is genuinely adequate
For an uncomplicated patient with a clear history, a well-designed questionnaire reviewed by a licensed clinician is a reasonable standard of care and is how a large share of prescriptions in this category are written. It is faster, cheaper and no less careful when the intake is designed to surface contraindications.
It is weaker where the history is complicated, where the answers need follow-up questions, or where somebody is likely to under-report. A video visit is not automatically better care, but it is harder to complete on autopilot.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 20 programmes we price, that runs from $145 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
4 of those programmes charge a recurring platform fee on top of medication and 19 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
4 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded semaglutide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
What you are actually paying a platform for
A telehealth subscription bundles four things frequently priced as one: a clinical review, a prescription, fulfilment through a pharmacy, and ongoing access to someone who will answer a question. Programmes differ enormously in how much of each they provide.
None of that difference is visible in a monthly price, which is why two programmes charging the same figure can be very different purchases.
The test that separates care from a vending machine
Can this programme decline to prescribe? A service guaranteeing approval before a clinician has reviewed a history is not running a clinical process, whatever else it discloses. The most reassuring thing a telehealth service can do is turn someone away.
What we could not measure
Response times, whether the same clinician sees you twice, and how a programme behaves when a shipment fails. Those decide satisfaction more than price does and none is observable from outside, so they are absent from every table here rather than estimated into a score.
The usable proxy is what a programme publishes before it has your money.
Reading this against the rest of the decision
This sits inside a decision with three parts: what you pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.
They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interruption is a clinical event rather than an inconvenience — semaglutide takes sixteen weeks to re-titrate from the starter dose.
Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest on the site.
What to do with this before you enrol
Turn it into two or three questions you can send in an email. Anything here that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.
The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.
If a programme declines to answer, that is an answer. The market currently offers 20 priced alternatives, the cheapest verified at $145 a month all-in at a maintenance dose.
Reading this alongside the rest of the site
Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.
If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.
What we would need to change our mind
A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.
All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.
What this site will not do
Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.
Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.
Who this site is not for
Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.
If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.
The short version of prescription portability
Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.
Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $145 a month all-in, about $1,740 across a first year including titration.
The next step that actually moves things
Send two or three programmes the same five questions: total at 2.4 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
One thing worth doing annually
Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and semaglutide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.
An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.